Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

Anthony Mato, MD, Boxiong Tang, MD PhD, Soraya Azmi, MBBS,MPH, Keri Yang, PhD MPH, MS, Jennifer C Stern, PhD, Eric Hedrick, MD, Jane Huang, MD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-134119

Published: 2020

Journal Articles

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Constantine S. Tam, MD, Hang Quach, MBBS, MD, Andrew Nicol, Xavier Badoux, Hannah Rose, H. Miles Prince, MD FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, Richard Eek, MBCHB, Nicholas Wickham, FRCPA,FRACP,FRCPath, Sushrut S. Patil, FRACP, FRCPA, Jane Huang, MD, Xiaoping Zhang, MD PhD, Lai Wang, PhD, Eric Hedrick, MD, William Novotny, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 1745.

https://doi.org/10.1182/blood.V130.Suppl_1.1745.1745

Published: 2017

Journal Articles

The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL

Louis M. Staudt, MD, PhD, Kieron Dunleavy, MD, Joseph J. Buggy, PhD, Eric Hedrick, MD, Nicole Lucas, RN, Stefania Pittaluga, MD, Sameer Jhavar, MD, Roland Schmitz, PhD, Mickey Williams, Ph.D., Jason Lih, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2011) 118 (21): 2716.

https://doi.org/10.1182/blood.V118.21.2716.2716

Published: 2011

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

Susan O'Brien, MD, Jan A. Burger, MD, PhD, Kristie A. Blum, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Jeff Sharman, MD, Ian W. Flinn, MD, PhD, Barbara Grant, MD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Tasheda Navarro, Eric Holmgren, PhD, Eric Hedrick, MD, John C. Byrd, MD

Blood (2011) 118 (21): 983.

https://doi.org/10.1182/blood.V118.21.983.983

Published: 2011

Journal Articles

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

Luhua Wang, MD, Peter Martin, MD, Kristie A. Blum, MD, Brad S. Kahl, MD, Lauren S. Maeda, MD, Ranjana Advani, MD, Michael E. Williams, MD, Simon Rule, MD, Sara Rodriguez, Ching-Fai Pang, PhD, Eric Hedrick, MD, Andre Goy, MD

Blood (2011) 118 (21): 442.

https://doi.org/10.1182/blood.V118.21.442.442

Published: 2011

NARROW

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

Email alerts

ASH Publications

American Society of Hematology

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only